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To determine patterns and predictors of antimicrobial
drug use for outpatients with community-acquired pneumo-
nia, we examined office visit and pharmacy claims data of
4 large third-party payer organizations from 2000 to 2002.
After patients with coexisting conditions were excluded,
4,538 patients were studied. Despite lack of coexisting con-
ditions, fluoroquinolone use was commonly observed
and increased significantly (p < 0.001) from 2000 to 2002
(24%–39%), while macrolide use decreased (55%–44%).
Increased age correlated with increased fluoroquinolone
use: 18–44 years (22%), 45–64 years (33%), and >65
years (40%) (p < 0.001). Increased use of fluoroquinolones
occurred in healthy young and old patients alike, which
suggests a lack of selectivity in reserving fluoroquinolones
for higher risk patients. Clear and consistent guidelines are
needed to address the role of fluoroquinolones in treatment
of outpatient community-acquired pneumonia.
C
ommunity-acquired pneumonia (CAP) is a leading
cause of death due to infection in the United States
and a primary indication for antimicrobial drug use in
inpatient and outpatient settings. The fluoroquinolone
class of antimicrobial agents has become increasingly pop-
ular for the management of CAP because of coverage of
common CAPpathogens, toleration by patients, and excel-
lent oral absorption (1). “Respiratory” fluoroquinolones,
such as levofloxacin, gatifloxacin, moxifloxacin, and
gemifloxacin, have activity against most strains of drug-
resistant Streptococcus pneumoniae (DRSP) (2). Concerns
for infection due to DRSP may drive fluoroquinolone use
because providers fear that traditional CAP regimens will
fail (3,4). However, fluoroquinolone resistance, while gen-
erally low, appears to be increasing in S. pneumoniae
(5–8). Therapeutic failures have been reported in patients
infected with fluoroquinolone-resistant organisms treated
with levofloxacin (9,10). Although data from community
settings are lacking, resistance to fluoroquinolones is also
increasing among gram-negative organisms in hospital set-
tings (11,12). Increased use of fluoroquinolones for outpa-
tient respiratory tract infections may lead to increased
resistance rates among community-acquired gram-nega-
tive organisms. Fluoroquinolones may promote coloniza-
tion and infection with methicillin-resistant
Staphylococcus aureus (MRSA) (13–15). Community-
acquired MRSA infections, once rare, have increased in
frequency (16,17).
Clinicians are faced with the dilemma of attempting to
limit broad-spectrum antimicrobial drug use on a popula-
tion level while trying to maximize therapeutic success in
individual patients (18). Routine prescribing of fluoro-
quinolones for CAP may limit the possibility of therapeu-
tic failure due to drug-resistant organisms but may
compromise the future effectiveness of this class of drugs.
Practice guidelines available for management of CAPfrom
various professional societies provide mixed messages on
the use of fluoroquinolones, particularly for patients eligi-
ble for outpatient treatment. The American Thoracic
Society recommends reserving fluoroquinolones for out-
patients with cardiopulmonary disease or other modifying
factors, advocating a macrolide or doxycycline for patients
without such coexisting conditions (19). The Drug-
Resistant Streptococcus pneumoniae Working Group rec-
ommends reserving fluoroquinolones for patients whose
treatment has failed on other regimens or those with docu-
mented infections due to DRSP (20). Previous guidelines
of the Infectious Diseases Society of America considered
macrolides, doxycycline, or fluoroquinolones as equiva-
lent options for treating outpatients, with the suggestion
that older patients and those with underlying disease have
a stronger indication for fluoroquinolone therapy (21). A
recent update of these guidelines categorizes patients
according to whether they recently received antimicrobial
drugs and presence of underlying conditions: patients
without underlying illnesses and no recent antimicrobial
drug therapy should receive a macrolide or doxycycline,
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groups (22). Such extensive subclassification and conflict
among guidelines may pose difficulties for clinicians prac-
ticing in busy outpatient settings (23). Without clear and
consistent guidelines, clinicians may base their therapeutic
decisions on tradition, the practice of colleagues, or advice
from pharmaceutical sales representatives, rather than the
best evidence.
We examined a database of office visit and pharmacy
claims from 4 large managed-care organizations in
Colorado. Our objective was to determine the patterns of
antimicrobial drug prescribing, especially fluoroquinolone
use, in a group of outpatients with CAP without serious
underlying conditions. 
Methods
We used administrative claims data from 4 healthcare
organizations in Colorado. Identifiable patient information
was removed before the information was provided, and
patients were assigned a unique identification number for
the purpose of data manipulation. Information contained in
the database included the patient’s date of birth, sex, visit
date, health plan, provider identification and specialty, up
to 3 International Classification of Diseases, 9th edition,
Clinical Modification (ICD-9-CM) diagnostic codes, and
drugs prescribed during the visit. Data were available from
March 1, 2000, to March 1, 2003. The study received
approval from the institutional review board of the
University of California, San Francisco.
Our criteria for inclusion in the study were age >18
years, primary diagnosis of CAP (based on ICD-9-CM
codes 481, 482, 483, 485, and 486), and prescription of an
antimicrobial agent associated with the visit. As serious
coexisting conditions may justify the use of fluoro-
quinolones according to some guidelines, we excluded
those patients with coexisting conditions to examine pre-
scribing patterns in an otherwise healthy population.
Specifically, we excluded patients who had a second or
third diagnosis of chronic obstructive pulmonary disease,
congestive heart failure, diabetes, lung cancer, renal fail-
ure, atrial fibrillation, respiratory failure, pleural effusion,
Parkinson disease, multiple sclerosis, and asphyxia. We
excluded patients who had sought treatment for an acute
respiratory tract infection (bronchitis, pharyngitis, otitis
media, sinusitis, and upper respiratory tract infection) or
urinary tract infection during the 4 weeks before the visit
for pneumonia. Consequently, we excluded results for the
first month of the study (March 2000) since data regarding
prior visits were unavailable for that group. Finally, we
limited the dataset to 1 pneumonia visit per patient to
reduce the likelihood of including patients whose previous
therapy had been unsuccessful. We categorized patients by
age into 3 strata: 18–44 years, 45–64 years, and >65 years.
We also categorized patients according to health plan (1
through 4). For categorization by year, we used March 1 as
the start and end date (e.g., year 2001 was March 1, 2001,
to March 1, 2002). 
Antimicrobial agents were identified by using National
Drug Codes. Antimicrobial drugs were assigned to one of
the following categories: tetracyclines (doxycycline, tetra-
cycline), macrolides (azithromycin, clarithromycin, eryth-
romycin), fluoroquinolones (ciprofloxacin, levofloxacin,
ofloxacin, moxifloxacin, gatifloxacin), aminopenicillins
(amoxicillin, amoxicillin/clavulanate), cephalosporins
(primarily cefuroxime and cefprozil), sulfonamides
(trimethoprim-sulfamethoxazole), and other. Only 1
antimicrobial agent was recorded per patient visit. We used
the visit date to analyze data by year of prescription (2000,
2001, or 2002).
Comparisons between proportions in groups were per-
formed by using the Mantel-Haenszel χ2 test for trend,
with a significance level of 0.05. Logistic regression analy-
sis was performed on the group of patients without coex-
isting conditions. The outcome was prescription of a
fluoroquinolone. Variables included in the model were
year of treatment, age (by category), patient sex, and
health plan; and interactions between year of treatment
with age, patient sex, and health plan were also tested. All
analyses were performed by using SAS, version 8.2 (SAS,
Cary, NC, USA).
Results
Inclusion criteria were met by 5,001 patients in our
database. Of our sample, 463 patients were excluded
because of >1 conditions. Excluded patients were more
likely to be in 1 of the older age categories (p < 0.001).
Characteristics of the final group of study patients (N =
4,538) without coexisting conditions are presented in
Table 1. 
Data from the 4,538 patients were analyzed to deter-
mine use of antimicrobial agents. Figure 1 shows changes
in antimicrobial prescribing from 2000 to 2002 for all
patients. Use of fluoroquinolones increased from 25% of
all prescriptions in 2000 to 39% in 2002 (p < 0.001).
Macrolide use decreased from 55% in 2000 to 44% in
2002 (p < 0.001). Aminopenicillin use (≈9%) did not
change significantly, but cephalosporin use decreased by
almost half (7% to 4%). Use of tetracyclines, sulfa drugs,
and other antimicrobial agents was minimal. Of note, flu-
oroquinolone use in the 18- to 44-year age group more
than doubled from 2000 to 2002 (14% to 30%)
Figure 2 shows the distribution of antimicrobial pre-
scribing between the 3 age categories for all years in the
study. Use of fluoroquinolones differed significantly
between groups (p < 0.001); patients in the oldest group
received more fluoroquinolones (40%) than those in the
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Macrolide use was highest in persons 18–44 years (61%),
followed by those 44–65 years (49%) and persons >65
years (37%) (p < 0.001). Differences in prescribing of
aminopenicillins, cephalosporins, and tetracyclines also
were observed across age groups. Among fluoro-
quinolones prescribed over all years of the study, 74%
were for levofloxacin; among all macrolides, 72% were for
azithromycin.
Results of logistic regression analysis to determine pre-
dictors of fluoroquinolone use are presented in Table 2.
When the 45- to 64-year age group was used as a referent,
patients in the older group were more likely, and those in
the younger group less likely, to receive fluoroquinolones.
Likelihood of fluoroquinolone use also differed signifi-
cantly by health plan: 1 health plan was less likely to pre-
scribe fluoroquinolones. The interaction between year of
prescription and age category was of marginal significance
(p = 0.0855), which suggests that increases in fluoro-
quinolone use were similar across age groups. However, a
significant interaction occurred between year of prescrip-
tion and health plan (p < 0.0001), which indicates that
changes in fluoroquinolone prescription rates differed by
health plan.
Discussion
We found significant changes in the pattern of antimi-
crobial prescribing for the outpatient management of
patients with CAP from 2000 to 2002. Fluoroquinolone
use increased by >50%, from 25% to 39% of all prescrip-
tions. This increase was at the expense of the macrolide
class of antimicrobial drugs, the use of which declined
20% during the study period. Use of β-lactam drugs and
doxycycline was low throughout the study period.
Although fluoroquinolones were prescribed for older
patients more frequently than for younger patients, the
growth in fluoroquinolone use over the study was similar
across all age groups.
Few published studies have documented trends in use
of fluoroquinolones for the management of respiratory
tract infections in the community. No study has specifical-
ly addressed the use of fluoroquinolones for pneumonia. In
a national sample of U.S. office-based physicians from
1992 to 2000, a 78% increase in the use of fluoro-
quinolones across all indications was documented (24).
Chen et al. noted a 5-fold increase in community fluoro-
quinolone prescribing for all indications in Canada from
1988 to 1997 (5). In a survey of U.S. community-based
prescribing from 1991 to 1999, use of fluoroquinolones for
upper respiratory tract infections in adults increased from
<1% to 13% of antimicrobial drug prescriptions (25). 
A number of factors may contribute to the observed
increased fluoroquinolone use, including the convenience
of once-daily dosing, reliable spectrum of activity against
CAP pathogens, and relatively low toxicity. In addition,
changes in health plan formularies, pharmaceutical adver-
tising, and concerns about resistance to standard therapies
may have influenced these prescribing trends. 
We found age-specific differences among patients for
whom fluoroquinolones were prescribed. Patients in the
older age groups were more likely to receive fluoro-
quinolones than those in persons 18–44 years, even after
those with underlying conditions were excluded. Age itself
may be an important underlying condition as well as a risk
factor for drug-resistant S. pneumoniae (26). Thus, clini-
cians may choose to use drugs they perceive to be more
potent to reduce the risk for treatment failure in this popu-
lation. In a survey of fluoroquinolone use from the
National Hospital Ambulatory Medical Care Survey from
1993 to 1998, persons >65 years of age had the highest use
of fluoroquinolones (12.4 prescriptions/100 persons/year,
compared to a mean of 4.6/100 persons/year for all groups)
(27). 
A recent study evaluated outpatient fluoroquinolone
use for CAP in 6 emergency departments in Canada (28).
The most commonly prescribed antimicrobial drugs were
macrolides (53%) and fluoroquinolones (32%; 98% of
these prescriptions were for levofloxacin). Similar to our
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Figure 1. Antimicrobial drug treatment of outpatient pneumonia by
year. Percentage of all study patients receiving a particular class
of antimicrobial drug for an episode of community-acquired pneu-
monia for each year of the study, across all age groups.  results in this study, increasing age was a significant pre-
dictor of levofloxacin use; 25% of patients 16–40 years of
age received levofloxacin, compared to 28% of those
41–64 years and 47% of those ≥65 years. We also deter-
mined appropriateness of levofloxacin use on the basis of
Canadian guidelines. When we used an interpretation of
these guidelines in which fluoroquinolone use in all
patients with chronic obstructive pulmonary disease or
recent antimicrobial drug use was considered appropriate,
51% of levofloxacin prescriptions were considered inap-
propriate. 
We did not have adequate information to fully assess
appropriateness of therapy, and the lack of agreement
among currently published U.S. guidelines prevents estab-
lishing a universal benchmark. However, in the absence of
coexisting conditions, the prognosis for patients <45 years
of age with CAP is favorable. The American Thoracic
Society, as well as CDC, recommends use of either a
macrolide or doxycycline in this group (current Infectious
Diseases Society of America guidelines would use a fluo-
roquinolone if the patient had recently used an antimicro-
bial agent). Although fewer fluoroquinolones were used in
the younger age groups, substantial use was noted in all
age groups, and increases in the rate of fluoroquinolone
use were independent of age group. These findings suggest
that those prescribing antimicrobial drugs may be increas-
ingly using fluoroquinolones as a “one-size-fits-all” regi-
men without accounting for differences due to age and
other risk factors. Clarifying the appropriateness of fluoro-
quinolone use on the basis of patient characteristics should
be a goal of future joint guidelines for CAP. We also
observed that patterns of fluoroquinolone prescribing var-
ied across health plans. Although this finding probably
reflects differences in each health plan’s pharmacy benefits
management programs, our study did not collect informa-
tion to help further characterize this finding. Further inves-
tigation of the differences between these programs is
warranted because these studies might identify or inform
effective interventions to reduce excess fluoroquinolone
prescribing.
Our study has a number of limitations. The cohort con-
sists of patients seen in a particular geographic area.
Antimicrobial drug use may vary significantly by region.
The dataset consisted of patients enrolled in managed-care
organization healthcare plans. Prescribing patterns for
these patients may differ from those for other populations.
The database captured only the first 3 ICD-9 codes associ-
ated with a patient visit, which we used to exclude patients
with notable underlying conditions. Some coexisting con-
ditions may have been coded as fourth or fifth diagnoses,
or not coded at all, in which case our sample would not
have excluded all patients with these coexisting conditions
as we planned. We did not measure outcomes, such as
return visits or deaths, to assess the effectiveness of the
prescribed regimens. We were not able to exclude all
patients with recent antimicrobial drug therapy. However,
we did exclude patients with a recent visit for an acute res-
piratory infection or urinary tract infection, many of whom
would have received an antimicrobial drug. We also did
not have data on local antimicrobial resistance patterns to
assess appropriateness of empiric therapy or changes in
resistance over the course of the study.
In summary, our study demonstrates an increase in flu-
oroquinolone use to treat outpatient CAP among a cohort
without complicating coexisting conditions. This increas-
ing use of fluoroquinolones, especially in otherwise
healthy patients whose infections are not likely to fail to
respond to treatment or whose infections are not likely to
be caused by resistant organisms, may threaten the future
effectiveness of this drug class. Harmonization of expert
guidelines regarding the role of fluoroquinolones in the
outpatient management of CAP is recommended.
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Figure 2. Antimicrobial drug treatment of outpatient pneumonia by
age. Percentage of all study patients receiving a particular class of
antimicrobial drug for an episode of community-acquired pneumo-
nia by age group, across all study years.This study was supported by an unrestricted research grant
from Abbott Laboratories, Inc., using data collected as part of a
research project sponsored by the Agency for Healthcare
Research and Quality (#1 R01 HS13001; R. Gonzales, Principal
Investigator).
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